Association between sitagliptin plus vitamin D3 (VIDPP-4i) use and clinical remission in patients with new-onset type 1 diabetes: a retrospective case-control study
ABSTRACT Objective: The occurrence of partial remission (honeymoon phase) in type 1 diabetes (T1D) has been associated with a reduced risk of chronic microvascular complications of diabetes. We have published case reports showing that a combination therapy with the DPP-4 inhibitor sitagliptin plus...
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Brazilian Society of Endocrinology and Metabolism
2023-06-01
|
| Series: | Archives of Endocrinology and Metabolism |
| Subjects: | |
| Online Access: | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S2359-39972023000500214&lng=en&tlng=en |
| _version_ | 1797810368940081152 |
|---|---|
| author | Marcelo Maia Pinheiro Felipe Moura Maia Pinheiro Marcelo Müller de Arruda Geane Moron Beato Graciele Alves Corrêa Lima Verde Georgiana Bianchini Pedro Rosário Moraes Casalenuovo Aline Aparecida Agostini Argolo Lucilene Telles de Souza Flávia Gomes Pessoa Thiago Santos Hirose Eduardo Filgueiras Senra Camillo Ricordi Andrea Fabbri Marco Infante Susana Nogueira Diniz |
| author_facet | Marcelo Maia Pinheiro Felipe Moura Maia Pinheiro Marcelo Müller de Arruda Geane Moron Beato Graciele Alves Corrêa Lima Verde Georgiana Bianchini Pedro Rosário Moraes Casalenuovo Aline Aparecida Agostini Argolo Lucilene Telles de Souza Flávia Gomes Pessoa Thiago Santos Hirose Eduardo Filgueiras Senra Camillo Ricordi Andrea Fabbri Marco Infante Susana Nogueira Diniz |
| author_sort | Marcelo Maia Pinheiro |
| collection | DOAJ |
| description | ABSTRACT Objective: The occurrence of partial remission (honeymoon phase) in type 1 diabetes (T1D) has been associated with a reduced risk of chronic microvascular complications of diabetes. We have published case reports showing that a combination therapy with the DPP-4 inhibitor sitagliptin plus vitamin D3 (VIDPP-4i) can prolong the honeymoon phase in patients with new-onset T1D. In the present case-control study, we investigated the frequency of occurrence of clinical remission (CR) in patients with new-onset T1D after VIDPP-4i treatment. Subjects and methods: In this case-control study, we collected data spanning 10 years from medical records of 46 patients (23 females) recently diagnosed with T1D. Overall, 27 participants with CR (insulin dose-adjusted glycated hemoglobin [IDAA1c] ≤ 9) at 12 or 24 months composed the case group, and 19 participants without CR served as the control group. Chi-square with Yates correction was used to analyze the association between VIDPP-4i use and CR, and odds ratio (OR) was used to determine the chance of CR due to VIDPP-4i treatment exposure. Results: In all, 37 patients (80.4%) experienced CR at some time over 24 months. The mean CR duration was 13.15 ± 9.91 months. Treatment with VIDPP-4i was significantly associated with CR. At 24 months, the OR of CR after VIDPP-4i exposure was 9.0 (95% confidence interval [CI] 2.21-30.18, p = 0.0036). Additionally, 9 (33.6%) and 4 (14.8%) patients in the VIDPP-4i group experienced insulin-free CR at 12 and 24 months, respectively. Conclusion: Therapy with VIDPP-4i was associated with a higher frequency and duration of the honeymoon phase. Randomized controlled trials are needed to confirm these findings. |
| first_indexed | 2024-03-13T07:07:47Z |
| format | Article |
| id | doaj.art-9d74899d9f984e3ab2ada60c44c48448 |
| institution | Directory Open Access Journal |
| issn | 2359-4292 |
| language | English |
| last_indexed | 2024-03-13T07:07:47Z |
| publishDate | 2023-06-01 |
| publisher | Brazilian Society of Endocrinology and Metabolism |
| record_format | Article |
| series | Archives of Endocrinology and Metabolism |
| spelling | doaj.art-9d74899d9f984e3ab2ada60c44c484482023-06-06T07:34:38ZengBrazilian Society of Endocrinology and MetabolismArchives of Endocrinology and Metabolism2359-42922023-06-0167510.20945/2359-3997000000652Association between sitagliptin plus vitamin D3 (VIDPP-4i) use and clinical remission in patients with new-onset type 1 diabetes: a retrospective case-control studyMarcelo Maia Pinheirohttps://orcid.org/0000-0003-3287-0476Felipe Moura Maia Pinheirohttps://orcid.org/0000-0002-9627-8407Marcelo Müller de Arrudahttps://orcid.org/0000-0001-6655-221XGeane Moron Beatohttps://orcid.org/0000-0003-1340-076XGraciele Alves Corrêa Lima Verdehttps://orcid.org/0000-0002-1966-9375Georgiana Bianchinihttps://orcid.org/0000-0003-2531-3786Pedro Rosário Moraes Casalenuovohttps://orcid.org/0000-0003-3595-4720Aline Aparecida Agostini Argolohttps://orcid.org/0000-0003-3183-9530Lucilene Telles de Souzahttps://orcid.org/0000-0001-9525-3403Flávia Gomes Pessoahttps://orcid.org/0000-0002-8170-221XThiago Santos Hirosehttps://orcid.org/0000-0001-8654-0590Eduardo Filgueiras Senrahttps://orcid.org/0000-0001-5444-5978Camillo Ricordihttps://orcid.org/0000-0001-8092-7153Andrea Fabbrihttps://orcid.org/0000-0003-2269-1554Marco Infantehttps://orcid.org/0000-0003-2032-8735Susana Nogueira Dinizhttps://orcid.org/0000-0002-4329-848XABSTRACT Objective: The occurrence of partial remission (honeymoon phase) in type 1 diabetes (T1D) has been associated with a reduced risk of chronic microvascular complications of diabetes. We have published case reports showing that a combination therapy with the DPP-4 inhibitor sitagliptin plus vitamin D3 (VIDPP-4i) can prolong the honeymoon phase in patients with new-onset T1D. In the present case-control study, we investigated the frequency of occurrence of clinical remission (CR) in patients with new-onset T1D after VIDPP-4i treatment. Subjects and methods: In this case-control study, we collected data spanning 10 years from medical records of 46 patients (23 females) recently diagnosed with T1D. Overall, 27 participants with CR (insulin dose-adjusted glycated hemoglobin [IDAA1c] ≤ 9) at 12 or 24 months composed the case group, and 19 participants without CR served as the control group. Chi-square with Yates correction was used to analyze the association between VIDPP-4i use and CR, and odds ratio (OR) was used to determine the chance of CR due to VIDPP-4i treatment exposure. Results: In all, 37 patients (80.4%) experienced CR at some time over 24 months. The mean CR duration was 13.15 ± 9.91 months. Treatment with VIDPP-4i was significantly associated with CR. At 24 months, the OR of CR after VIDPP-4i exposure was 9.0 (95% confidence interval [CI] 2.21-30.18, p = 0.0036). Additionally, 9 (33.6%) and 4 (14.8%) patients in the VIDPP-4i group experienced insulin-free CR at 12 and 24 months, respectively. Conclusion: Therapy with VIDPP-4i was associated with a higher frequency and duration of the honeymoon phase. Randomized controlled trials are needed to confirm these findings.http://www.scielo.br/scielo.php?script=sci_arttext&pid=S2359-39972023000500214&lng=en&tlng=enCholecalciferolDPP-4 inhibitorhoneymoon phasetype 1 diabetesvitamin D |
| spellingShingle | Marcelo Maia Pinheiro Felipe Moura Maia Pinheiro Marcelo Müller de Arruda Geane Moron Beato Graciele Alves Corrêa Lima Verde Georgiana Bianchini Pedro Rosário Moraes Casalenuovo Aline Aparecida Agostini Argolo Lucilene Telles de Souza Flávia Gomes Pessoa Thiago Santos Hirose Eduardo Filgueiras Senra Camillo Ricordi Andrea Fabbri Marco Infante Susana Nogueira Diniz Association between sitagliptin plus vitamin D3 (VIDPP-4i) use and clinical remission in patients with new-onset type 1 diabetes: a retrospective case-control study Archives of Endocrinology and Metabolism Cholecalciferol DPP-4 inhibitor honeymoon phase type 1 diabetes vitamin D |
| title | Association between sitagliptin plus vitamin D3 (VIDPP-4i) use and clinical remission in patients with new-onset type 1 diabetes: a retrospective case-control study |
| title_full | Association between sitagliptin plus vitamin D3 (VIDPP-4i) use and clinical remission in patients with new-onset type 1 diabetes: a retrospective case-control study |
| title_fullStr | Association between sitagliptin plus vitamin D3 (VIDPP-4i) use and clinical remission in patients with new-onset type 1 diabetes: a retrospective case-control study |
| title_full_unstemmed | Association between sitagliptin plus vitamin D3 (VIDPP-4i) use and clinical remission in patients with new-onset type 1 diabetes: a retrospective case-control study |
| title_short | Association between sitagliptin plus vitamin D3 (VIDPP-4i) use and clinical remission in patients with new-onset type 1 diabetes: a retrospective case-control study |
| title_sort | association between sitagliptin plus vitamin d3 vidpp 4i use and clinical remission in patients with new onset type 1 diabetes a retrospective case control study |
| topic | Cholecalciferol DPP-4 inhibitor honeymoon phase type 1 diabetes vitamin D |
| url | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S2359-39972023000500214&lng=en&tlng=en |
| work_keys_str_mv | AT marcelomaiapinheiro associationbetweensitagliptinplusvitamind3vidpp4iuseandclinicalremissioninpatientswithnewonsettype1diabetesaretrospectivecasecontrolstudy AT felipemouramaiapinheiro associationbetweensitagliptinplusvitamind3vidpp4iuseandclinicalremissioninpatientswithnewonsettype1diabetesaretrospectivecasecontrolstudy AT marcelomullerdearruda associationbetweensitagliptinplusvitamind3vidpp4iuseandclinicalremissioninpatientswithnewonsettype1diabetesaretrospectivecasecontrolstudy AT geanemoronbeato associationbetweensitagliptinplusvitamind3vidpp4iuseandclinicalremissioninpatientswithnewonsettype1diabetesaretrospectivecasecontrolstudy AT gracielealvescorrealimaverde associationbetweensitagliptinplusvitamind3vidpp4iuseandclinicalremissioninpatientswithnewonsettype1diabetesaretrospectivecasecontrolstudy AT georgianabianchini associationbetweensitagliptinplusvitamind3vidpp4iuseandclinicalremissioninpatientswithnewonsettype1diabetesaretrospectivecasecontrolstudy AT pedrorosariomoraescasalenuovo associationbetweensitagliptinplusvitamind3vidpp4iuseandclinicalremissioninpatientswithnewonsettype1diabetesaretrospectivecasecontrolstudy AT alineaparecidaagostiniargolo associationbetweensitagliptinplusvitamind3vidpp4iuseandclinicalremissioninpatientswithnewonsettype1diabetesaretrospectivecasecontrolstudy AT lucilenetellesdesouza associationbetweensitagliptinplusvitamind3vidpp4iuseandclinicalremissioninpatientswithnewonsettype1diabetesaretrospectivecasecontrolstudy AT flaviagomespessoa associationbetweensitagliptinplusvitamind3vidpp4iuseandclinicalremissioninpatientswithnewonsettype1diabetesaretrospectivecasecontrolstudy AT thiagosantoshirose associationbetweensitagliptinplusvitamind3vidpp4iuseandclinicalremissioninpatientswithnewonsettype1diabetesaretrospectivecasecontrolstudy AT eduardofilgueirassenra associationbetweensitagliptinplusvitamind3vidpp4iuseandclinicalremissioninpatientswithnewonsettype1diabetesaretrospectivecasecontrolstudy AT camilloricordi associationbetweensitagliptinplusvitamind3vidpp4iuseandclinicalremissioninpatientswithnewonsettype1diabetesaretrospectivecasecontrolstudy AT andreafabbri associationbetweensitagliptinplusvitamind3vidpp4iuseandclinicalremissioninpatientswithnewonsettype1diabetesaretrospectivecasecontrolstudy AT marcoinfante associationbetweensitagliptinplusvitamind3vidpp4iuseandclinicalremissioninpatientswithnewonsettype1diabetesaretrospectivecasecontrolstudy AT susananogueiradiniz associationbetweensitagliptinplusvitamind3vidpp4iuseandclinicalremissioninpatientswithnewonsettype1diabetesaretrospectivecasecontrolstudy |